Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

Trial Profile

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hypericin (Primary)
  • Indications Cutaneous T-cell lymphoma; Mycosis fungoides
  • Focus Registrational; Therapeutic Use
  • Acronyms FLASH
  • Sponsors Soligenix
  • Most Recent Events

    • 03 Oct 2019 According to a Soligenix media release, the Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation to review the companys two pivotal phase 3 clinical programs in cutaneous T-cell lymphoma (FLASH) and oral mucositis in head and neck cancer (DOMINNATE) at the Global Chinese Financial Forum (GCFF) Conference on 5th Oct 2019 (Vancouver, BC, Canada).
    • 23 Apr 2019 According to the Soligenix media release, company anticipate completing study enrollment in the second half of 2019 and expects final top-line results in Q1 2020.
    • 22 Oct 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top